BioCentury | Oct 17, 2020
Finance

Menlo to continue healthcare push at intersection of tech, life sciences with $500M fund

...the firm doesn’t have a target allocation for healthcare but it might devote “a little bit...
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...valuations in Europe and been interested because the quality of the assets here are every bit...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

...don’t need to be involved for a bit...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

...added that a vaccine “could be announced in October, it could be announced a little bit...
BioCentury | Sep 11, 2020
Product Development

Loxo’s Bilenker on why reimbursement crisis is creating innovation, access crises: a BioCentury audio interview

...way towards the willingness to assume a bit...
...and so it's rational to "take a bit...
...reverse be enacted here? That seems a bit...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

...confidence, because what worries me a little bit...
...really interesting. Can you go a little bit...
...question. And it reminds me a little bit...
BioCentury | Sep 10, 2020
Product Development

U.S. needs master protocols such as U.K.’s RECOVERY to speed COVID-19 evidence collection, McClellan says: a BioCentury audio interview

...clinical trials. Can you talk a little bit...
...that are going on. But with a bit...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

...why it's important, what you're doing, that doesn't work well because scientists have a little bit...
...mean, there is a good vision. There is a great vision, but I'm a little bit...
...preclinical model, which was not what you were looking for, but what represents a little bit...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

...COVID-19. However, she noted there’s still “a bit...
...[00:08:06] Simone Fishburn: Let's talk a little bit...
...U.S. government has put in quite a bit...
BioCentury | Sep 10, 2020
Product Development

Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview

...they attitudinal? [00:14:33] Martin Landray: There a bit...
Items per page:
1 - 10 of 824
BioCentury | Oct 17, 2020
Finance

Menlo to continue healthcare push at intersection of tech, life sciences with $500M fund

...the firm doesn’t have a target allocation for healthcare but it might devote “a little bit...
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...valuations in Europe and been interested because the quality of the assets here are every bit...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

...don’t need to be involved for a bit...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

...added that a vaccine “could be announced in October, it could be announced a little bit...
BioCentury | Sep 11, 2020
Product Development

Loxo’s Bilenker on why reimbursement crisis is creating innovation, access crises: a BioCentury audio interview

...way towards the willingness to assume a bit...
...and so it's rational to "take a bit...
...reverse be enacted here? That seems a bit...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

...confidence, because what worries me a little bit...
...really interesting. Can you go a little bit...
...question. And it reminds me a little bit...
BioCentury | Sep 10, 2020
Product Development

U.S. needs master protocols such as U.K.’s RECOVERY to speed COVID-19 evidence collection, McClellan says: a BioCentury audio interview

...clinical trials. Can you talk a little bit...
...that are going on. But with a bit...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

...why it's important, what you're doing, that doesn't work well because scientists have a little bit...
...mean, there is a good vision. There is a great vision, but I'm a little bit...
...preclinical model, which was not what you were looking for, but what represents a little bit...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

...COVID-19. However, she noted there’s still “a bit...
...[00:08:06] Simone Fishburn: Let's talk a little bit...
...U.S. government has put in quite a bit...
BioCentury | Sep 10, 2020
Product Development

Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview

...they attitudinal? [00:14:33] Martin Landray: There a bit...
Items per page:
1 - 10 of 824